Controlled Deposition of Paclitaxel and Limus-Based Formulations: Lab-Scale Coating Workflow with UMC7300 Balloon Catheter Coating System

Laboratory coating work for cardiovascular devices often begins with a practical question: how can a formulation be applied to a small, complex surface in a controlled and repeatable way? An Ultrasonic Balloon Catheter Coating System such as the UMC7300 can support early studies of formulation deposition, process development and prototype production. Results should be evaluated for the specific device and formulation rather than treated as proof of finished-device performance.

Paclitaxel-based formulations may be explored for drug-coated balloon catheters, while limus-based formulations may be investigated for drug-eluting coronary stents. These are distinct development paths. Drug selection, excipients, solvents, substrate properties and intended release characteristics all influence the questions a laboratory needs to answer.

Step 1: Define the device and coating objective

Describe the substrate, geometry, intended coated area and development stage. For balloons, note relevant folds, transitions and the intended coating region. For stents, document the design features that may affect access to struts and open spaces. Define the desired coating attributes and the methods that will be used to assess them.

Step 2: Prepare and document the formulation

Follow approved laboratory procedures for formulation preparation, handling and storage. Record composition, preparation date, relevant material properties and any observed changes during use. Formulations should be assessed for compatibility and stability by qualified personnel. This workflow does not prescribe a universal recipe or solvent for paclitaxel or limus compounds.

Consider the difference between solution and suspension systems

Whether a formulation is a solution or suspension can change how it behaves during delivery and deposition. Stability, settling, viscosity and surface interaction may need to be studied. Use appropriate controls and analytical methods to confirm that the formulation remains suitable for the planned experiment.

Step 3: Set up the coating trial

Use the equipment documentation to establish a suitable starting setup, fixture and motion plan. Confirm that the device is positioned consistently and that the target area can be accessed. Record the selected settings and sample identification so another team member can understand how the run was performed. Do not rely on undocumented assumptions about output, droplet size or coating speed.

Step 4: Apply the coating in a controlled sequence

Plan the sequence of passes, part movement and any intervals required by the formulation and laboratory procedure. Observe whether material accumulates at edges, folds, stent features or other local areas. If the trial is intended to compare settings, change factors according to a predefined plan and keep other conditions as consistent as practical.

Step 5: Dry, inspect and characterise

Use a defined post-coating procedure and document relevant environmental conditions. Inspect samples using suitable methods for the attribute under study. Depending on the project, assessment may include coverage, morphology, local accumulation, adhesion, drug distribution, residual solvent or integrity after a device-specific handling step. Select tests based on the device risk and intended use.

Step 6: Review and refine

Compare results against the criteria established before the run. Keep complete records, including failed or inconclusive trials. Repeat promising conditions to understand variability and confirm that the result is not a one-off observation. Only after sufficient evidence is gathered should a candidate process move into more formal development and validation activities.

Learn more about the ultrasonic drug balloon coating machine and Cheersonic’s approach to ultrasonic atomizing coating.

Frequently asked questions

1. Is the same workflow suitable for paclitaxel and limus formulations?

The overall documentation structure can be similar, but the formulation, process window, analytical tests and acceptance criteria should be tailored to each drug-device combination.

2. Does controlled deposition guarantee a specific drug-release profile?

No. Release behaviour depends on the full formulation, coating structure, device and test conditions. It must be evaluated with suitable, validated methods.

3. What should be recorded for each prototype?

Record sample identity, substrate, formulation batch and preparation, equipment setup, process settings, environmental conditions, post-coating handling and inspection or analytical results.

4. Can sample coating replace process validation?

No. Sample trials support feasibility and process development. Formal validation and device-specific safety and performance evaluations remain separate activities.

Plan a sample coating test with Cheersonic

Qualified medical-device manufacturers, R&D teams and production engineers are invited to contact Cheersonic to discuss their medical-device coating project and arrange a sample coating test. Email market2@cheersonic.com with a summary of the device, formulation and research objectives.